Cymabay Therapeutics Inc (CBAY) - News Archive

Showing 4 of 4 results.

CymaBay Announces European Medicines Agency Accepts Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics Inc (Nasdaq: CBAY) has recently announced that the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for Seladelpar, a potential treatment for Primary Biliar...

Mar 4, 2024 • Major Pharmaceutical Preparations Industry Management Announcement

CymaBay Therapeutics Rises with Inducement Grants and Public Offering Success

CymaBay Therapeutics Continues to Make Strides with Inducement Grants and Public OfferingIn a recent press release, CymaBay Therapeutics, Inc. announced the grant of inducement awards to three employees on February 16,...

Feb 20, 2024 • Major Pharmaceutical Preparations Industry Shares

CymaBay Thrives with $225 Million Public Offering and Inducement Grants for New Employees

CymaBay Therapeutics, a renowned clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases, recently announced the grant of inducement awards to four employees in acco...

Dec 18, 2023 • Major Pharmaceutical Preparations Industry Shares

CymaBay Therapeutics Inc. Raises $225 Million in Public Offering: A Boost for Innovative Therapies and Stock Performance.

CymaBay Therapeutics Inc. Raises $225 Million in Public Offering - Impact on Share PriceAs of the writing of this article, CymaBay Therapeutics Inc. (Nasdaq: CBAY) has announced the pricing of its upsized public offerin...

Sep 12, 2023 Shares